DOJ Grants First Healthcare Declination Under New Corporate Enforcement Policy While Indicting Founder

On July 29, 2026, the Department of Justice (“DOJ”) announced that, consistent with Part I of DOJ’s Department-wide Corporate Enforcement and Voluntary Self-Disclosure Policy (“CEP”), it declined to prosecute Campus Eye Management Holdings LLC and its wholly owned subsidiary, Campus Eye Management LLC (collectively, “Campus Eye”), a management services organization that provided billing and other services to an optometry practice and ambulatory surgery center. DOJ had been investigating Campus Eye for alleged healthcare fraud, including illegal kickbacks. This is the first declination involving a healthcare company under the new, Department-wide CEP.  And it is only the second healthcare fraud declination under any voluntary self-disclosure policy in DOJ history—the first being the HealthSun Health Plans, Inc. matter handled by the same team (i.e., the Health Care Fraud Unit) when they were part of the Criminal Division’s Fraud Section, prior to creation of the National Fraud Enforcement Division (“NFED”) earlier this year.

As discussed here, the CEP generally provides a path to declination for companies that voluntarily self-disclose misconduct, fully cooperate, timely and appropriately remediate, and agree to pay required restitution or victim compensation and forfeiture or disgorgement, as applicable, absent specified aggravating circumstances. In explaining the Campus Eye resolution, DOJ cited the company’s timely and voluntary disclosure; full and proactive cooperation, including its agreement to continue cooperating in related investigations and prosecutions (presumably, the prosecution of Campus Eye’s founder, E. Bruce DiDonato); timely and appropriate remediation; the absence of aggravating factors; and its agreement to compensate victims. Regarding remediation, DOJ highlighted that Campus Eye’s efforts included reviewing and revising certain billing, payment, and compensation policies; conducting ongoing risk assessments and monitoring; hiring personnel with compliance responsibilities; and implementing compliance training.

The corporate declination was announced alongside a seven-count indictment of E. Bruce DiDonato. In that case, DOJ alleges that, from at least 2015 through March 2023, DiDonato conspired to defraud Medicare by billing for unnecessary or duplicative diagnostic eye tests and paid kickbacks and bribes to ophthalmologists in exchange for patient referrals. The government further alleges that the payments were concealed through sham consulting agreements and purported monthly “flat fees” that were actually based on a percentage of Medicare reimbursements generated by referred patients. DiDonato allegedly caused the submission of approximately $3.4 million in fraudulent Medicare claims. DOJ’s announcement points out that DiDonato then used those reimbursements to pitch and sell Campus Eye to private equity investors. It would seem those investors then uncovered and reported the fraud to the government through the CEP.

The matter illustrates DOJ’s effort to pair incentives for corporate self-reporting with the continued prosecution of allegedly responsible individuals (i.e., individual accountability) and provides an early healthcare example of how DOJ will apply the CEP.

Significantly, as to structure and DOJ operations, the announcement also highlights that it’s not only the legacy Criminal Division, Fraud Section, Health Care Fraud Unit that has migrated to NFED; personnel from the Fraud Section’s former Corporate Enforcement and Compliance Unit have also shifted. Specifically, the release accompanying the declination described Marnee Rand as Acting Chief of the National Fraud Enforcement Division’s Corporate Enforcement Section.  This strongly signals that NFED will, like the Fraud Section before it, be focused on corporate prosecutions and resolutions in addition to pursuit of investigations against individuals.

This post is as of the posting date stated above. Sidley Austin LLP assumes no duty to update this post or post about any subsequent developments having a bearing on this post.